Previous close | 130.94 |
Open | 135.75 |
Bid | 138.46 x 100 |
Ask | 139.30 x 100 |
Day's range | 134.68 - 142.22 |
52-week range | 126.97 - 266.67 |
Volume | |
Avg. volume | 244,953 |
Market cap | 14.997B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.45 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 272.77 |
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...